Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Merck
Accenture
Cipla
Deloitte
Fuji
Baxter
QuintilesIMS
Mallinckrodt
Healthtrust

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,107,898

« Back to Dashboard

Which drugs does patent 9,107,898 protect, and when does it expire?

Patent 9,107,898 protects SILENOR and is included in one NDA.

This patent has ten patent family members in four countries.
Summary for Patent: 9,107,898
Title:Methods of using low-dose doxepin for the improvement of sleep
Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
Inventor(s): Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan E. (Carlsbad, CA), Jochelson; Philip (San Diego, CA), Kavey; Neil B. (Chappaqua, NY)
Assignee: Pernix Sleep, Inc. (Morristown, NJ)
Application Number:13/492,559
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,107,898

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pernix Theraps Llc SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF INSOMNIA ➤ Sign Up
Pernix Theraps Llc SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF INSOMNIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,107,898

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,513,299 Methods of using low-dose doxepin for the improvement of sleep ➤ Sign Up
9,498,462 Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders ➤ Sign Up
9,801,847 Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders ➤ Sign Up
9,463,181 Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders ➤ Sign Up
9,486,437 Methods of using low-dose doxepin for the improvement of sleep ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,107,898

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2687118 ➤ Sign Up
Canada 2687124 ➤ Sign Up
European Patent Office 2026792 ➤ Sign Up
Japan 2009537553 ➤ Sign Up
Japan 2009537554 ➤ Sign Up
Japan 2013237694 ➤ Sign Up
Japan 2016041757 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2007136845 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2007142810 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2007142811 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Citi
Accenture
Chinese Patent Office
Johnson and Johnson
Argus Health
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot